RZLT · XBRL financial data

Rezolute financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (RZLT's year ends in late June)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Research and development	14,987	32,486	43,813	55,743	61,527	53,798
General and administrative	7,907	9,357	12,177	14,680	18,367	29,168
Total operating expenses	22,894	41,843	55,990	70,423	79,894	82,966
Operating income (loss)	(22,894)	(41,843)	(55,990)	(70,423)	(79,894)	(82,966)
Interest expense	375	—	—	—	—	—
Income tax expense (benefit)	0	0	0	0	0	0
Net income (loss)	(20,902)	(41,060)	(51,787)	(68,459)	(74,412)	(77,586)
Earnings per share, basic USD per share	(2.72)	(2.26)	(1.01)	(1.33)	(0.98)	(0.75)
Earnings per share, diluted USD per share	(2.72)	(2.32)	(1.01)	(1.33)	(0.98)	(0.75)
Weighted average shares, basic thousands of shares	7,671	18,197	51,187	51,465	75,999	103,907
Weighted average shares, diluted thousands of shares	7,671	19,487	51,187	51,465	75,999	103,907

Fiscal years (RZLT's year ends in late June)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Cash and cash equivalents	41,047	150,410	16,036	70,396	94,107	10,615
Marketable securities	—	—	85,860	56,478	73,751	97,186
Marketable securities, non-current	—	—	16,470	263	—	—
Prepaid and other current assets	946	1,694	3,014	1,779	3,287	2,710
Total current assets	41,993	152,104	104,910	128,653	171,145	110,511
Property and equipment, net	29	16	139	103	72	41
Right-of-use asset	396	152	2,054	1,880	1,348	769
Total assets	42,609	152,420	123,721	132,737	175,490	112,849
Accounts payable	1,035	1,132	3,269	4,901	5,809	5,026
Total current liabilities	1,968	2,462	5,200	9,606	11,912	11,418
Lease liability, non-current	187	80	1,937	1,660	983	276
Total liabilities	16,510	2,949	7,549	11,734	13,363	12,162
Accumulated deficit	(168,138)	(209,198)	(260,985)	(329,444)	(403,856)	(481,442)
Total stockholders' equity	26,099	149,471	116,172	121,003	162,127	100,687
Total liabilities and equity	42,609	152,420	123,721	132,737	175,490	112,849
Common shares outstanding (cover page) thousands of shares	8,620	38,828	36,828	55,370	90,811	96,722

Fiscal years (RZLT's year ends in late June)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Net income (loss)	(20,902)	(41,060)	(51,787)	(68,459)	(74,412)	(77,586)
Stock-based compensation	3,965	3,685	7,268	7,360	7,121	14,460
Net cash from operating activities	(20,441)	(39,616)	(44,481)	(57,368)	(69,075)	(64,635)
Purchases of property and equipment	—	—	153	—	—	—
Net cash from investing activities	0	—	(101,464)	48,699	(14,541)	(21,098)
Proceeds from issuing common stock	0	—	—	—	—	—
Share repurchases	—	—	—	3	—	—
Net cash from financing activities	51,533	148,979	11,571	63,029	107,327	2,241
Net change in cash	31,092	109,363	(134,374)	54,360	23,711	(83,492)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Rezolute	10,615	not reported	(13,146)*	96.7M	8.2 quarters	Q4 FY26 10-KJun 30, 2026
Cardiff Oncology	9,197	104	(11,765)*	77.8M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Silence Therapeutics	72,054	0	1,518*	141.7M	—	Q2 FY26 10-QJun 30, 2026
Tvardi Therapeutics	15,765	not reported	(9,228)*	13.3M	1.7 quarters	Q2 FY26 10-QJun 30, 2026
Esperion Therapeutics	156,158	80,104	(27,722)	257.4M	5.6 quarters	Q1 FY26 10-QMar 31, 2026
Natures Sunshine Products	82,503	116,985	835*	17.6M	—	Q2 FY26 10-QJun 30, 2026
Palvella Therapeutics	187,803	not reported	(12,845)*	14.4M	19.5 quarters	Q2 FY26 10-QJun 30, 2026
Rocket Pharmaceuticals	224,507	0	(39,613)*	109.8M	7.2 quarters	Q2 FY26 10-QJun 30, 2026
Perspective Therapeutics	48,488	not reported	(20,650)*	114.2M	11.5 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.